Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study

Basit Öğe Kaydı
dc.contributor.authorHepsen, Sema
dc.contributor.authorHaymana, Cem
dc.contributor.authorCavnar Helvaci, Burcak
dc.contributor.authorDurantas, Halil
dc.contributor.authorToros, Bora
dc.contributor.authorCakmak, Ramazan
dc.contributor.authorGuven, Mehmet
dc.date.accessioned2026-04-04T13:33:05Z
dc.date.available2026-04-04T13:33:05Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground : The study aimed to evaluate real-world data on liraglutide by assessing its efficacy, associated side effects, adverse events, and impact on metabolic parameters within the context of a multicenter national study. Methods : This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from T & uuml;rkiye. Patients with a history of bariatric surgery, those who started orlistat concurrently with liraglutide, and one patient who developed pancreatitis on the 15th day of treatment were excluded from the analyses of weight and laboratory changes. Results : At least one side effect was observed in 48% of the patients, with nausea and vomiting being the most common. The most frequent reason for discontinuing treatment was the cost of the medication (42.6%). The median duration of liraglutide use was 4 months (IQR; 3-6), and the median dose was 2.4 mg (IQR; 1.8-3). Among the entire cohort, 76.4% and 40.9% of patients achieved a 5% and 10% weight loss target, respectively. Significant reductions were observed in metabolic parameters during the treatment. The treatment duration was identified as an independent predictor for achieving 5% and 10% weight loss targets (B = 0.315, p < 0.001) and 10% weight loss (B = 0.216, p < 0.001). Conclusions : Liraglutide effectively results in clinically significant weight loss, achieves expected weight loss targets, and improves metabolic parameters in real-world clinical practice. Therefore, liraglutide is still a reasonable GLP-1 analogue in the obesity treatment. However, it may be associated with various side effects, necessitating close monitoring by clinicians.
dc.identifier.doi10.1186/s40001-025-02836-5
dc.identifier.issn0949-2321
dc.identifier.issn2047-783X
dc.identifier.issue1
dc.identifier.orcid0000-0002-8375-7409
dc.identifier.orcid0000-0001-5577-700X
dc.identifier.orcid0000-0002-5145-0920
dc.identifier.orcid0000-0002-2315-9458
dc.identifier.pmid41074095
dc.identifier.urihttps://doi.org/10.1186/s40001-025-02836-5
dc.identifier.urihttps://hdl.handle.net/11616/108919
dc.identifier.volume30
dc.identifier.wosWOS:001591872900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofEuropean Journal of Medical Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectGLP-1 analogue
dc.subjectLiraglutide
dc.subjectObesity
dc.subjectOverweight
dc.titleComprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu